Written question asked by Jim Shannon (Democratic Unionist Party) on Monday, 7 September 2015, in the House of Commons. It was due for an answer on Wednesday, 9 September 2015. It was answered by George Freeman (Conservative) on Tuesday, 15 September 2015 on behalf of the Department of Health.
Co-careldopa
- Question
-
To ask the Secretary of State for Health, what steps he is taking to introduce the drug Duodopa for the treatment of NHS patients with Parkinson's disease.
- Answer
-
On 2 July 2015, NHS England announced that Duodopa will now be routinely commissioned by NHS England for patients meeting the inclusion criteria agreed by the Neurosciences Clinical Reference Group.
The specific commissioning policy on Duodopa is available here:
http://www.england.nhs.uk/commissioning/spec-services/npc-crg/group-d/d04/
This decision followed a three-month public consultation on the principles and processes NHS England will follow when making investment decisions.
Secondary information
- Type
- Written question
- Reference
- 9295
- Session
- 2015-16
- Subjects
- Co-careldopa
- Link
- View this Written question on www.parliament.uk
Librarians' tools
- Timestamp
- 2024-05-29 09:08:58 +0100
- URI
- http://data.parliament.uk/writtenparliamentaryquestion/commons/2015-16/9295
- In Indexing
- http://indexing.parliament.uk/Content/Edit/1?uri=http://data.parliament.uk/writtenparliamentaryquestion/commons/2015-16/9295
- In Solr
- https://search.parliament.uk/claw/solr/?id=http://data.parliament.uk/writtenparliamentaryquestion/commons/2015-16/9295